limonoid glucosides (13). These glucosides are responsible for two experiments in male F344 rats. In a pilot study, we delayed bitterness in citrus juices and processed products examined the modifying effects of obacunone and limonin (15) . Obacunone and limonin have been reported to enhance on AOM-induced (20 mg/kg body wt, once a week for 2 glutathione S-transferase (GST) activity in various organs of weeks) formation of aberrant crypt foci (ACF). Dietary mice (16,17). Limonin and nomilin are reported to inhibit feeding of both compounds at dose levels of 200 and forestomach, buccal pouch, lung and skin carcinogenesis in 500 p.p.m. during AOM exposure for 4 weeks ('initiation' feeding) or after AOM treatment for 4 weeks ('postrodents (18). However, the modifying effects of the citrus initiation' feeding) significantly inhibited ACF formation limonoids obacunone and limonin on large bowel carcino-(55-65% reduction by 'initiation' feeding, P < 0.001; 28-genesis have not been reported. 42% reduction by 'post-initiation' feeding, P < 0.05-0.002).
We have previously reported the chemopreventive ability of In a long-term study designed to confirm the protective natural compounds from edible plants against colon carcinoeffects of obacunone and limonin on ACF development, genesis using aberrant crypt foci (ACF) as a biomarker (19, 20) . one group was treated with AOM alone and another ACF in the colon of rodents (exposed to colonic carcinogens) four groups received the carcinogen treatment plus diets and humans are regarded as possible precursor lesions for containing 500 p.p.m. test compounds for 3 weeks (initiation colon cancers (21,22) and as useful biomarkers for detecting phase) or 29 weeks (post-initiation phase). Two groups the modulatory effects of xenobiotics on colon carcinogenesis were treated with obacunone or limonin alone (500 p.p.m.
(23). We have identified several natural agents from edible in diet) and one group was maintained on the basal plants using this ACF assay model (19). These include inducers diet. At the termination of the study, dietary exposure to of GST and quinone reductase (QR) activities in liver and obacunone or limonin during the initiation phase was found colon (24-27). Obacunone and limonin could induce GST to have significantly reduced the incidence of colonic activity in certain organs (18) and limonin could inhibit adenocarcinoma (72 versus 25 or 6%, P ⍧ 0.004 or carcinogen-DNA adduct formation (18). We also recently 0.00003). Obacunone or limonin feeding during the postfound that dietary administration of both compounds increase initiation phase also reduced the frequency of colonic GST and QR activities in liver and colon of rats (T.Tanaka adenocarcinoma (72 versus 13%, P ⍧ 0.0002). Our results et al., manuscript in preparation). Therefore, it is possible that suggest that the citrus limonoids obacunone and limonin these compounds inhibit colon carcinogenesis. might be useful for the prevention of human colon cancers.
In the present study, two experiments were conducted to investigate the modifying effects of obacunone and limonin on large bowel tumorigenesis induced by azoxymethane (AOM) in rats. In a pilot study, dietary obacunone and limonin were Dietary factors play an important role in prevention of various given to rats in order to determine whether these compounds human diseases, including cancers (1-3). Experimental and epidemiological evidence suggests that increased dietary could modulate the occurrence of ACF. Subsequently, a longfiber is associated with reduced risk of colon cancer, which is term bioassay was performed to confirm and evaluate the the third most malignant neoplasm in the world (4) and the preventive effects of dietary obacunone and limonin on AOMsecond leading cause of cancer deaths in the USA. An estimated induced colon carcinogenesis. 875 000 new cases were reported in 1996, accounting for Four-week-old male F344 rats (Shizuoka Laboratory Animal 8.5% of all new cases of cancer in the world. In Japan, the Center, Shizuoka, Japan) were used. All animals were housed progressive introduction of Western dietary habits, especially in wire cages (three or four rats per cage) with free access to increased fat intake and reduced carbohydrate and dietary fiber drinking water and basal diet (CE-2; CLEA Japan, Tokyo, Japan), under controlled conditions of humidity (50 Ϯ 10%), lighting (12 h light/dark cycle) and temperature (23 Ϯ 2°C). In a pilot study, 104 rats were divided into 12 groups as shown in Figure 2a . Groups 1-9 received two weekly s.c. injections of AOM at a dose of 20 mg/kg body wt. Rats of group 1 were fed the basal diet alone while those of groups 2 and 3 were fed diets containing 200 p.p.m. obacunone and limonin, respectively, for 4 weeks, starting 1 week before the first dose of AOM. Similarly, groups 4 and 5 were given the experimental diets containing 500 p.p.m. obacunone and limonin, respectively, for 4 weeks, starting 1 week before the first injection of AOM. Groups 6 and 7 were fed diets containing 200 p.p.m. obacunone and limonin, respectively, for 4 weeks, commencing 2 weeks after the last dose of AOM. Groups 8 and 9 were fed diets containing 500 p.p.m. obacunone and limonin, respectively, for 4 weeks, starting 2 weeks after the last injection of AOM. Groups 10 and 11 were fed the experimental diet containing 500 p.p.m. obacunone or limonin alone for 8 weeks and did not receive AOM. Group 12 was an untreated control. At weeks 4 and 8, eight rats from each The colons of all rats in the pilot study were used for death (no. of rats); u, basal diet, CE-2; o, 500 p.p.m. obacunone in diet; l, scoring of ACF. At autopsy, the colons were flushed with 500 p.p.m. limonin in diet.
saline, excised, cut open longitudinally along the main axis and then washed again with saline. The colons were cut into three sections (~4 cm each) starting from the anus, placed 29 weeks of the post-initiation phase, starting 1 week after the last administration of AOM. Groups 6 and 7 did not receive between filter papers to reduce mucosal folding and fixed in 10% buffered formalin for at least 24 h. Fixed colonic sections AOM and were fed diets mixed with 500 p.p.m. obacunone or limonin for the duration of the study (32 weeks). Group were dipped in a 0.2% solution of methylene blue in distilled water for 30 s and briefly rinsed with distilled water. Using 8 served as an untreated control. All rats were carefully observed daily, weighed weekly until they reached 14 weeks a light microscope at a magnification of ϫ40, ACF were distinguished from surrounding normal crypts by their large of age and every 4 weeks thereafter. Consumption of the experimental diets was also recorded to estimate the intake of size, more prominent epithelial cells and increased pericryptal space. The number of ACF observed per colon, number of test compounds. The experiment was terminated 32 weeks after commencement and all animals were killed by an ether aberrant crypts observed in each focus and location of each focus were recorded.
overdose to assess the incidences of large bowel tumors, kidney mesenchymal tumors and altered liver cell foci. At For the long-term study (Figure 2b ), a total of 113 rats were randomly divided into eight groups. Groups 1-5 received two autopsy, the intestine was excised, opened longitudinally, flushed clean with saline and examined for the presence of weekly s.c. injections of AOM (20 mg/kg body wt). Rats in groups 2 and 3 were fed diets containing 500 p.p.m. obacunone tumors. Colons, kidney and liver were fixed in 10% buffered formalin and then processed for histopathological examination and limonin for 3 weeks, respectively, commencing 1 week before the first dose of AOM. Groups 4 and 5 were fed the diet by conventional methods. Neoplasms in the intestine were diagnosed according to the criteria described by Ward (28). If mixed with 500 p.p.m. obacunone and limonin, respectively, for tumor cells of tubular form invaded the submucosa, the ACF/colon in groups 2-5 was significantly less than that in group 1 (P Ͻ 0.001). As indicated in Table II , the 'post-initiation' tumor was diagnosed as adenocarcinoma. When the tumor cells did not invade the submucosa, the tumor was diagnosed as feeding of 500 p.p.m. obacunone and limonin significantly decreased the body weight gains in groups 7 and 9 at weeks 8 adenoma. Other organs were also examined histopathologically.
One-factor ANOVA, the Kruskal-Wallis test or Fisher's (P Ͻ 0.02 and 0.05), but did not affect the liver weights (9.9 Ϯ 1.3-11.4 Ϯ 1.2 g) or liver weight:body weight ratio exact probability test was used for statistical analyses. A value of P Ͻ 0.05 was considered significant. The experimental (4.05 Ϯ 0.36-4.45 Ϯ 0.38%). The mean number of aberrant crypts/focus of groups 6-9 was significantly smaller than in protocol was approved by the Ethics Review Committee for Animal Experimentation of Kanazawa Medical University. group 1 (P Ͻ 0.001).
In the long-term bioassay, the daily food intake of groups In the pilot study, the mean daily intakes of diets mixed with obacunone and limonin during AOM exposure (groups 2-7 did not differ from that of groups 1 and 8, which were fed the basal diet without obacunone or limonin (data not 2-5) were between 14.1 and 14.7 g/rat, while those in groups 1, 10, 11 and 12 were between 14.6 and 15.1 g/rat (weeks 0-4).
shown). In this study, dietary administration of the two test compounds did not cause any clinical signs of toxicity, low The mean daily intakes of diets mixed with obacunone and limonin after AOM exposure (groups 1 and 6-12) were between survival or poor clinical condition. Weight gains of rats in all groups were comparable throughout the experimental period. 16.9 and 17.4 g/rat (weeks 4-8). During the study (8 weeks) , no clinical signs of toxicity were observed in any group. HistoAt the end of the study, the mean liver weights and relative liver weights (g/100 g body wt) of all groups except that of logically, there were no toxic changes in the liver, kidneys, lung and heart of the rats in any group. At the commencement of the group 5, which was fed 500 p.p.m. limonin after AOM treatment, were also comparable (Table III) . Both the mean study there was no difference in body weights of the animals among the treatment groups. The 'initiation' feeding of obacuand relative liver weights of group 5 were significantly lower than those of group 1 (P Ͻ 0.05). none and limonin (groups 2-5) significantly inhibited body weight gains at week 4, when compared with that of group 1 Macroscopically, most tumors developed in the large intestine (mainly the middle and distal colon) and some in the (P Ͻ 0.01 or 0.001), as shown in Table I . The range of liver weight and the liver weight:body weight ratio (%) were small intestine of rats in groups 1-5. They were sessile or pedunculated tumors histologically diagnosed as tubular 10.0 Ϯ 0.4-11.8 Ϯ 2.0 g and 4.83 Ϯ 0.17-5.82 Ϯ 0.70%, respectively. All animals administered AOM in all treatment adenomas, tubular adenocarcinomas or mucinous carcinomas, with a higher incidence of tubular adenocarcinoma. A few rats groups contained at least one ACF. The incidence of in groups 1-5 had renal mesenchymal tumors and/or altered induced colonic ACF indicate that this biological marker of colon carcinogenesis may be useful for screening agents (19,29) hepatocellular foci, but these lesions were not evident in any other group. Animals of groups 6-8 did not have neoplasms for chemoprevention of colon tumorigenesis. This lesion has been suggested to be the premalignant lesion of chemically in any organs examined, including the intestines. The incidence and multiplicity of large bowel neoplasms are shown in Table  induced colon cancer (22). However, it would probably be prudent to use tumor incidence as the end point for definitive investi-IV. AOM administration was associated with an increased incidence of large intestinal adenocarcinomas (72%, 18 of 25 gations as there are many sites at which chemopreventive compounds may affect tumorigenesis (23). Both compounds rats) and with a multiplicity of 0.76 Ϯ 0.51. The incidences and multiplicities of groups 2-5 were significantly lower than tested in this study may have blocking and suppressing effects on AOM-induced colon tumorigenesis when fed in the diet those of group 1 (P ϭ 0.004, 0.00003 or 0.0002).
In the pilot study, dietary feeding of obacunone and during the initiation and post-initiation phases. Several dietary factors are known to modulate carcinogenesis limonin for 4 weeks either during or after AOM exposure significantly decreased development of ACF, suggesting that in humans (30) and rodents (31) . The results of the present study confirmed previous epidemiological data suggesting that the two chemicals tested could inhibit the growth of colonic ACF and suppress the progression of preneoplasia to maligconsumption of vegetables and/or fruits is inversely related to cancer risk, including colon cancer (6, 7, 32) . In the pilot study, nancy. Subsequent long-term experiments confirmed the results of the pilot study and indicated that the suppressing we observed no differential dose-response effect on ACF formation between 200 and 500 p.p.m. of the two limonoids. effects of both compounds fed to rats during either the initiation or post-initiation phase were significant. It should be
The reason for this is unknown, but it is likely that the dose of 200 p.p.m. is already above the threshold level for the noted, however, that since commercial orange juice contains 320 p.p.m. limonoid glucosides (13), the concentrations neceseffect. It would be interesting to investigate the effects of lower doses in future experiments. sary to achieve the effects observed in our study would bẽ 12-to 30-fold higher than those obtained from normal dietary One possible mechanism for the suppression of colonic tumor development might be through the control of cell ingestion of these limonoids. Our data suggest that obacunone and limonin are possible new dietary preventive agents against proliferation in ACF and/or 'normal appearing' crypts of rats exposed to AOM. Increased cell proliferation is colon cancer development. the inhibition correlates with suppression of cell proliferation and lipid peroxidation and with induction of phase II drug-metabolizing enzymes. Cancer Res., 58, 2550-2556. 25. Tanaka,T., Kawabata,K., Kakumoto,M., Makita,H., Ushida,J., Honjo,S.,
